Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination

Open Access

29 October 2007

journal article
Published by Springer Nature in Population Health Metrics

Vol. 5 (1) , 11
https://doi.org/10.1186/1478-7954-5-11

Abstract

To provide quantitative insight into current U.S. policy choices for cervical cancer prevention, we developed a model of human papillomavirus (HPV) and cervical cancer, explicitly incorporating uncertainty about the natural history of disease.

Keywords

This publication has 131 references indexed in Scilit:

Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland
British Journal of Cancer, 2007
Overview of the European and North American studies on HPV testing in primary cervical cancer screening
International Journal of Cancer, 2006
Cost-effectiveness of Extending Cervical Cancer Screening Intervals Among Women With Prior Normal Pap Tests
Obstetrics & Gynecology, 2006
The Elevated 10-Year Risk of Cervical Precancer and Cancer in Women With Human Papillomavirus (HPV) Type 16 or 18 and the Possible Utility of Type-Specific HPV Testing in Clinical Practice
JNCI Journal of the National Cancer Institute, 2005
Cost-effectiveness of Human Papillomavirus DNA Testing in the United Kingdom, The Netherlands, France, and Italy
JNCI Journal of the National Cancer Institute, 2005
Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis
British Journal of Cancer, 2003
Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis
British Journal of Cancer, 2003
Biotinyl-Tyramide-Based In Situ Hybridization Signal Patterns Distinguish Human Papillomavirus Type and Grade of Cervical Intraepithelial Neoplasia
Laboratory Investigation, 2002
ASCUS-LSIL Triage Study
Acta Cytologica, 2000
Natural History of Cervical Intraepithelial Neoplasia
International Journal of Gynecological Pathology, 1993